ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
The role of uric acid in Parkinson's disease: a UK brain bank pathology-validated case-control study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AI Video Analysis in Parkinson's Disease: A Systematic Review of the Most Accurate Computer Vision Tools for Diagnosis, Symptom Monitoring, and Therapy Management.Sensors (Basel, Switzerland) · 2025Pooled it
- Computer Vision Analysis for Objective Motor Assessment in Parkinson's Disease: A Retrospective Study.Movement disorders clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUric acid has been supposed to have a protective role in Parkinson's disease with controversial findings. This relationship has not been validated with pathology-confirmed diagnoses. This study aims to compare uric acid levels between pathology-confirmed and clinically-misdiagnosed Parkinson's disease patients over time.
methods65 patients with an in-vivo clinical diagnosis of Parkinson's disease were enrolled from the UK Brain Bank. 33 were confirmed with post-mortem pathology analysis, while 32 were clinically misdiagnosed patients. Chart review explored uric acid levels at two timepoints (NO and N1). A repeated-measures ANOVA evaluated uric acid level variation over time and determined differences between the groups, including timespan between samples, disease duration, age at death, age of onset and sex as covariates.
resultsAverage uric acid levels at N0 were 5.83 mg/dl (SD ± 1.99) and 5.94 mg/dl (SD ± 1.87) for respectively true and false positives. At N1, the values were 7.61 mg/dl (SD ± 2.35) and 7.36 mg/dl (SD ± 2.86) for respectively true and false positives. A significant main effect of time on uric acid levels was found (F(1, 58) = 4.303, p = 0.042, η
conclusionWhile uric acid levels increase over time in Parkinson's disease patients, this increase does not differ significantly between those with confirmed and unconfirmed diagnoses, nor it is influenced by disease duration, age at death, age of onset or sex.
Indexed as
Identifiers
40113639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.